208 related articles for article (PubMed ID: 22943618)
1. Applications of accelerator MS in pediatric drug evaluation.
Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
[TBL] [Abstract][Full Text] [Related]
2. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
3. Accelerator MS: its role as a frontline bioanalytical technique.
Seymour MA
Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
[TBL] [Abstract][Full Text] [Related]
4. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
Ings RM
Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
[TBL] [Abstract][Full Text] [Related]
5. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
Bae SK; Shon JH
Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
[TBL] [Abstract][Full Text] [Related]
6. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
Lappin G; Seymour M
Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
[TBL] [Abstract][Full Text] [Related]
7. Developing drugs for pediatric use: a role for juvenile animal studies?
Baldrick P
Regul Toxicol Pharmacol; 2004 Jun; 39(3):381-9. PubMed ID: 15135215
[TBL] [Abstract][Full Text] [Related]
8. When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies.
Arnold ME; Lacreta F
Bioanalysis; 2012 Aug; 4(15):1831-4. PubMed ID: 22943612
[No Abstract] [Full Text] [Related]
9. Stimulation programs for pediatric drug research--do children really benefit?
Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J
Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
[TBL] [Abstract][Full Text] [Related]
10. Microdosing Studies in Children: A US Regulatory Perspective.
Roth-Cline M; Nelson RM
Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
[TBL] [Abstract][Full Text] [Related]
11. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
12. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
[TBL] [Abstract][Full Text] [Related]
13. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
14. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
15. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
Lappin G; Stevens L
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
Young GC; Corless S; Felgate CC; Colthup PV
Rapid Commun Mass Spectrom; 2008 Dec; 22(24):4035-42. PubMed ID: 19009519
[TBL] [Abstract][Full Text] [Related]
17. Ethical implications of pediatric drug research policy initiatives.
Twomey JG
IRB; 2000; 22(2):5-10. PubMed ID: 11883466
[No Abstract] [Full Text] [Related]
18. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
[TBL] [Abstract][Full Text] [Related]
19. Drug therapy in childhood: what has been done and what has to be done?
Bartels H
Pediatr Pharmacol (New York); 1983; 3(3-4):131-43. PubMed ID: 6677868
[TBL] [Abstract][Full Text] [Related]
20. Criteria supporting the study of drugs in the newborn.
Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
